NOURNEWS - A knowledge-based company in Iran has made a new device to diagnose the specifications of cancerous tissues in patients.
“The machine produced in this company is a slide dyeing machine and a tissue processor. To diagnose the type and specifications of cancer, the target tissue should be processed. Actually, the device stains the target tissue in a different way,” Ramin Mohammadi Zand, the CEO of Sepehr Noafarin Sepehr Company, said.
He said slide dyeing and tissue processing "make different organs recognizable".
“In fact, this device realizes the possibility of processing, staining and studying the examined tissue and helps the medical staff to have a more accurate diagnosis of the disease,” Mohammadi Zand said.
He added that the newly-developed device can also be used in other fields, including botany, veterinary medicine or the food industry.
In a relevant development in August, Iranian researchers at a knowledge-based company in East Azarbaijan province’s Science and Technology Park had also succeeded in indigenization and production of mutation detection kits for K-Ras, B-raf and JAK2 genes by Real-Time PCR method.
“Diagnosis of Jak2 gene mutation is used to detect point somatic mutation of V617F in JAK2 gene and to assess risk in patients with polycythemia vera, thrombocythemia and promyelocytic leukemia, as well as to study responses to specific therapies which target JAK2,” Mehdi Haqqi, the founder of the knowledge-based company, told FNA.
He added that the kit has been indigenized and produced by Real-Time PCR method, noting that the price of foreign samples of this kit for 50 tests is over $3000, and the sample produced by Iranian scientists can be offered at a price of less than a quarter of the foreign models.
Last year, the Iranian researchers had also developed special kits to separate and count the cancer cells in patients' blood.
"In some patients who suffer from cancer, a part of the tissue is taken out for testing and then chemotherapy starts. These CTC kits help the physician to separate and count the cancer cells in the blood of patient before starting chemotherapy," Mehdi Rahimian, one of the researchers, said in June.
He added that after chemotherapy the physician should be assured that treatment has been effective and therefore, the CTC kits are needed again.
The laboratorial sample of the product has been designed and built and is ready to be produced and presented to the market, Rahimian said.
NOURNEWS